相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Differential Impact of Minimal Residual Disease Negativity According to the Salvage Status in Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
Elias Jabbour et al.
CANCER (2017)
Evaluation of allogeneic transplantation in first or later minimal residual disease - negative remission following adult-inspired therapy for acute lymphoblastic leukemia
Ryan D. Cassaday et al.
LEUKEMIA & LYMPHOMA (2016)
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
Hagop M. Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia
N. Goekbuget et al.
BLOOD CANCER JOURNAL (2016)
Antibodies: Immunoconjugates and autologous cellular therapy in acute lymphoblastic leukemia
Anjali Advani
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2015)
Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies
Jacques J. M. van Dongen et al.
BLOOD (2015)
Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment
Gerhard Zugmaier et al.
BLOOD (2015)
How I treat adults with relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia
Noelle V. Frey et al.
BLOOD (2015)
Relation of Clinical Response and Minimal Residual Disease and Their Prognostic Impact on Outcome in Acute Myeloid Leukemia
Xueyan Chen et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Acute Lymphoblastic Leukemia, Version 2.2015
Joseph C. Alvarnas et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2015)
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
Max S. Topp et al.
LANCET ONCOLOGY (2015)
Current status of antibody therapy in ALL
Jing Ai et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia
Anjali S. Advani et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
DNA released by leukemic cells contributes to the disruption of the bone marrow microenvironment
M. Dvorakova et al.
ONCOGENE (2013)
Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation
Nicola Goekbuget et al.
BLOOD (2012)
Modern Therapy of Acute Lymphoblastic Leukemia
Renato Bassan et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993
Bella Patel et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group
Albert Oriol et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Treatment of Adult Acute Lymphoblastic Leukemia
Nicola Goekbuget et al.
SEMINARS IN HEMATOLOGY (2009)
Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study
Adele K. Fielding et al.
BLOOD (2007)
Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia
M Brüggemann et al.
BLOOD (2006)
分享论文
